Pentec Health announced it is now offering prescription digital therapeutic (PDT) services through its newly created division, Pentec Home Medical. As part of its strategic expansion, Pentec has partnered with Luminopia Inc. to deliver distribution and support services to expand Luminopia’s market access, the company said in a press release. 

Luminopia’s flagship product, Luminopia, is an FDA-approved prescription digital therapeutic for amblyopia. By integrating advanced virtual reality technology with visual content and overlaying therapeutic algorithms, Luminopia provides an immersive, evidence-based approach to vision improvement.

Through this partnership, Pentec will act as a distribution and service provider for Luminopia, offering comprehensive support services to patients and providers. This includes navigating insurance to secure medical benefit coverage for authorization and medical necessity, and ensuring patient adherence for successful outcomes.

“At Pentec, we’re driven to innovate and simplify care delivery for complex, underserved markets," said Matthew Deans, CEO of Pentec Health, in the press release. "Our partnership with Luminopia marks a significant step in our expansion into digital therapeutic services, allowing us to bring a first-of-its-kind, FDA-approved vision therapy to children and families. We are excited to launch this new service and expand the care we deliver to more patients.” 

Luminopia CEO Scott Xiao added, “We are thrilled to partner with Pentec Health to enhance patient access to Luminopia. Pentec’s expertise in specialized clinical coordination and patient-centered support will ensure a seamless experience for patients and providers alike. Adding Pentec provides the flexibility to work with payers and expand coverage to patients in need, helping to navigate the complexities of medical benefits to ensure access to care. This collaboration is a shared mission of leveraging technology to improve vision health.”